KRYS 8-K 2026-11-02

Krystal Biotech, Inc. (KRYS) 8-K dated 2026-11-02 — accession 0001711279-26-000072.

Krystal Biotech, Inc. (KRYS) is a biotechnology company listed on NASDAQ.

KRYS: SECURITIES AND EXCHANGE COMMISSION

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported KRYS revenue for 2025-12-31 was $389.1M. Net income was $204.8M. Revenue was up 33.9% from 2024-12-31 to 2025-12-31. KRYS currently screens at market cap $10.17B and trailing P/E 41.6.

Not investment advice. The KRYS SEC hub lists recent forms. The stock page is the research view.